

IQVIA E360[™] Analytics Workbench and Analytics Methods Library

IQVIA's E360[™] Analytics Workbench provides a generalized framework for delivering sophisticated analytical methods that are portable across Real World Data sets.

It includes a rapidly growing pre-configured library of basic and advanced HEOR, Commercial and Machine-learning analytical methods along with an extensible framework for custom development.

With complex protocols and end points simulation, precise "what-if" analysis, incidence and prevalence analysis, and many other methods, Analytics Workbench has the right tool for the job at hand.

Analytics Workbench works on all E360[™] loaded datasets: OMOP, LPD and native format, and on non-E360[™] data.

KEY FUNCTIONALITY INCLUDES:

iliil.

Fully supports data generated by E360[™] Analytics Dataset Output from internal and external data sources Generate a variety of outputs from

Growing collection of Analytic Method categories

visualizations to tables



E360[™] Analytics Workbench to deliver on the promise of **"Any analytic method, and set of variables, any cohort, any dataset, anywhere"**.

$\equiv \in 360$ Workspaces					Jesus Vasquez 🔻
					0 ^
Project Me	2 thod [3 Data Source	Data Exploration	5 Publishing	Previous Next 6 Summary
Category	Q Selec	a method			
All	3)	tu nictiou			
Data Exploration Disease Occurence	6 3	Diving some filters, which Data Exploration Performs initial data explora dimensions (eigenvectors) fo	will affect your results. Clear i tion, covariance and correlation an or follow-on stages of analytical pip	filters alysis on all dimensions. Calculates prin reline.	ciple component
Brand Analytics and Prescription Modelling	3	Granularity: Patient Patient Characteristic Re Build Patient Characteristic	eport report of selected covariates and st	tratifications	
Commercial and Brand Analytics	4	Granularity: Patient			
Classical Statistical Applications	1	Incidence/Prevalence - Calculate incidence and pre	Chronic Conditions evalence for a chronic condition with	hin a cohort or entire database.	
Index and risk strata generation	○ ■	Matrix Report Build hierarchical matrix rep	ort of counts by selected covariate	S	
Genomic	2	Granularity: Any Logistic Regression Uses incremental logistic re	gression algorithms to produce and	I test predictive models for the risk of th	e final covariate
Granularity	THE REAL	based on all other covariate	is in the input data. Feature selection	on used to rank importance of covariates	i.
All	31	Granularity: Patient MH Cohort Match			
Patient	13 (⁸ 8)	Uses optimised Mahalanobi as an exposure condition. C	s algorithm to create matched coho alculates metrics for closeness of n	ort based on provided covariates agains natch for the generated cohort against t	t the final covariate he source cohort.
Event	14	Granularity: Patient			
	[هي	Propensity Score Match Uses Propensity Score Matc covariate as an exposure co cohort.) ching algorithm to create matched o ondition. Calculates metrics for close	cohort based on provided covariates ag eness of match for the generated cohor	ainst the final t against the source

Patients on Drug	Co-Medication	Compliance	Persistence	Sources of Business	Line of Therapy
					*
Patient Count 281	Patient Count 281				

The current methods library includes (but is not limited to):

DATA EXPLORATION

• Performs initial, simple descriptive data exploration, covariance and correlation analysis on all dimensions. The data exploration can be carried out on patient or event level data

PATIENT CHARACTERISTICS REPORT

 Allows you to build a typical 'Table 1'; a report providing distributions and summary statistics for selected covariates and stratifications

MATRIX REPORT

- A generalized multi-dimensional matrix report analysis. The matrix report is defined by:
 - » An ordered list of covariates to use for column definitions
 - » An ordered list of covariates to use for row definitions
 - » A list of covariates and aggregation functions for the cells within the matrix

ļ	AutoSave 💽 🗄 りゃ 🔍 🗢	Patient-C	Characteristics-CAD-16158	331842.xlsx - Excel	Search		Vasquez, Jesus VJ	🖻 – D X
File Home Insert Page Layout Formulas Data Review View Help								🖻 Share 🛛 🖓 Comments
Pa	$\begin{array}{c c} & & \\ \hline \\ \hline \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\$	- A^ A [*] - <u>A</u> -	≡ ≡ ≥ ≫ - ≡ ≡ ≡ •≡ •≡ ∎	General General • • % • 1	Conditional Fo Formatting ~ T	rrmat as Cell Table → Styles →	$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	Ideas Sensitivity
Cli	pboard 🕞 Font	F2	Alignment	r⊒ Number	r⊒ Sty	les Cells	Editing	Ideas Sensitivity ^
A1	\bullet : \times \checkmark f_x							v
	А		В	С	D	E	F	G
1			Full Cohort	Gender=Female	Gender=Male	Age at Index Date=3	Age at Index Date=4	Age at Index Date=5
2	Variable		Count (Percent)	Count (Percent)	Count (Percent)	Count (Percent)	Count (Percent)	Count (Percent)
3	N		4504 (100%)	2521 (100%)	1983 (100%)	112 (100%)	1379 (100%)	1947 (100%)
4	Gender							
5		Female	2521 (55.97%)	2521 (100.0%)	0	71 (63.39%)	814 (59.03%)	1106 (56.81%)
6		Male	1983 (44.03%)	0	1983 (100.0%)	41 (36.61%)	565 (40.97%)	841 (43.19%)
7	Age at Index Date							
8		3	112 (2.49%)	71 (2.82%)	41 (2.07%)	112 (100.0%)	0	0
9		4	1379 (30.62%)	814 (32.29%)	565 (28.49%)	0	1379 (100.0%)	0
10		5	1947 (43.23%)	1106 (43.87%)	841 (42.41%)	0	0	1947 (100.0%)
11		6	829 (18.41%)	418 (16.58%)	411 (20.73%)	0	0	0
12		7	180 (4.0%)	86 (3.41%)	94 (4.74%)	0	0	0
13		8	57 (1.27%)	26 (1.03%)	31 (1.56%)	0	0	0
14	Payer Type		4000 (44.00%)	4444 (44 400/)	004 (44 50%)	44 (20.2004)	574 (44 440()	000 (47 744)
15		C	1998 (44.36%)	1114 (44.19%)	884 (44.58%)	44 (39.29%)	571 (41.41%)	929 (47.71%)
10		CS M	917 (20.50%) 70 (1 FFW)	525 (20.75%)	394 (19.87%)	20 (17.86%)	525 (25.57%)	389 (19.98%)
17			70 (1.55%)	41 (1.05%)	29 (1.40%)	1 (0.69%)	5 (0.56%) 2 (0.15%)	14 (0.72%)
10		6	/1 (1.36%) 1444 (32.06%)	42 (1.07%) 709 (31.65%)	29 (1.40%)	17 (11 96%)	2 (0.13%)	9 (0.40%)
20		т	4 (0.09%)	3 (0 12%)	1 (0.05%)	47 (41.50%)	470 (34.32%)	000 (31.12%)
21	Geographic Region		4 (0.0576)	5 (0.1270)	1 (0.0576)	0	Ū	0
22		E	1185 (26,31%)	678 (26.89%)	507 (25.57%)	25 (22.32%)	336 (24,37%)	531 (27.27%)
23		MW	1564 (34,72%)	828 (32,84%)	736 (37.12%)	35 (31.25%)	473 (34.3%)	633 (32,51%)
24		S	1584 (35.17%)	928 (36.81%)	656 (33.08%)	47 (41.96%)	516 (37.42%)	719 (36.93%)
25		w	171 (3.8%)	87 (3.45%)	84 (4.24%)	5 (4.46%)	54 (3.92%)	64 (3.29%)
26	Health Plan Type							
27		-	659 (14.63%)	342 (13.57%)	317 (15.99%)	12 (10.71%)	191 (13.85%)	284 (14.59%)
28		D	2 (0.04%)	2 (0.08%)	0	0	0	1 (0.05%)
29		н	575 (12.77%)	342 (13.57%)	233 (11.75%)	10 (8.93%)	126 (9.14%)	225 (11.56%)
30		- E	47 (1.04%)	22 (0.87%)	25 (1.26%)	0	10 (0.73%)	13 (0.67%)
31		Р	2849 (63.25%)	1603 (63.59%)	1246 (62.83%)	84 (75.0%)	958 (69.47%)	1259 (64.66%)
32		S	237 (5.26%)	130 (5.16%)	107 (5.4%)	4 (3.57%)	62 (4.5%)	96 (4.93%)
33		U	135 (3.0%)	80 (3.17%)	55 (2.77%)	2 (1.79%)	32 (2.32%)	69 (3.54%)
	Patient Characteristics	+				: •		- F

INCIDENCE AND PREVALENCE

 The incidence and prevalence method for chronic and acute conditions allows users to get a better understanding of the disease occurrence within a population of interest by reporting on new (incident) and existing (prevalent) cases. It can be set to calculate incidence/prevalence rates by time periods (months and/or years), age groups and strata within the cohort.

COVID-19 INCIDENCE REPORT

 Report showing weekly incidence of Coronavirus Disease (COVID-19) cases based on US claims data

,	AutoSave 💽 🖪 りゃ 🔍 マ	Incidence	-Prevalence-CAD-16158328	57.xlsx - Excel	Search			ituli v	Vasquez, Jesus 🛛 🛛	- 1		
Fi	ile Home Insert Page Layout	Formulas	Data Review	View Help						🖻 Share 🖓 🛛	Comments	
Pa	Calibri Calibri Calibri B I U ~ [Clipboard □s Fe	- 11 - A ⊞ - <u>A</u> - nt		 → ab Wrap Text → B Merge & Center >> Nignment 	General ~ \$ ~ % 9 F3 Number	~ [.00 →0 Cor .00 →0 Form	ditional Format as for natting ~ Table ~ Sty Styles	Cell Insert Delete Format Cells	Z AutoSum ← A Fill ← Sort & Find & Clear ← Filter ← Select ← Editing	Ideas Sensitivity		~
M	7 • \vdots \times \checkmark f_x											~
	А	В	с	D	E	F	G	н	1	L L		
1	Summary by Calendar Year: Inciden	ce/Prevaler	nce of COPD Analytic D	Dataset cohort.								
2	Description	Stratification	Population contributing at least 1 day during period	Population at risk - Contributing at least 1 day during period	Person Days at Risk	Incidence Counts	Prevalence counts at period start	Incidence Rate (per 1,000 days ; 95	% CI) Incidence Proportion (95% C	() Point Prevalence (95% CI)	
3	Calendar Year	2017	3968	3917	1394284	35	51	0.025 (0.018 ; 0.035)	0.009 (0.006 ; 0.012)	0.013 (0.010 ; 0.	017)	
4		2018	4202	4116	1467597	56	86	0.038 (0.029 ; 0.050)	0.014 (0.010 ; 0.018)	0.020 (0.017 ; 0.	025)	
5		2019	4423	4281	1528727	47	142	0.031 (0.023 ; 0.041)	0.011 (0.008 ; 0.015)	0.032 (0.027 ; 0.	038)	
6 7 8 9 10	Notes: Only complete calendar years are consi Be aware that results obtained on incid Overall <u>Annual</u>	dered for inc ence and pre +	idence and prevalence c valence are sensitive to	alculations. Given a loo different sources of bia	wheack period of 1 years of a state of a state of the results ther	rear, only new e efore are indica	vent observations b tive and should be u : •	etween 01 Jan 2017 and 31 Dec 20 seed with caution.	019 (both dates inclusive) are o	onsidered as incider	nce cases.	Ŧ

Brand Analytics and Prescription Modelling:

PRESCRIPTION MODELLING

- The Prescription Modelling analytic method incorporates a complete set of individual analytics based on the ability to model and analyses patterns of prescription data.
- These analytics are:
 - Patients on Drug Analysis of the number of patients / prescriptions drug usage over time.
 Different charts produced for active prescriptions and patients on treatments etc. Multiple nested stratifications available
 - » Persistence Analysis of how long patients stay on a drug. Different charts produced for alternative views of this data. Multiple nested stratifications available
 - » Compliance Analysis of how patients comply with dosage recommendations – produces ratio of the total days supplied for each medication against the total length of time on the medication (Medical Possession Ratio)

- » Source of Business Analysis of the source of prescriptions – repeat prescriptions, new, switches from other drugs etc
- » **Comedication** Analysis of frequently used combinations of drug for the cohort/condition
- » Line of Therapy How patients move from one line of therapy / drug regimen to another
- In addition, optionally the following analytics can also be performed:
 - » **Total Dosage Calculation** Calculation of total dosage taken by patients
 - » Derived Data Set Generation The ability to build derived data sets from prescription data to enable follow-on analytics





Commercial and Brand Analytics

LINE OF THERAPY

· Line of Treatment provides a detailed, longitudinal view of treatment patterns and progression for patients. Line of Treatment addresses the issue of which stage the patient is treated with the brand over the whole course of treatment.

MEDICATION COMPLIANCE

• Use the Medication Possession Ratio (MPR) to assess compliance for a medication. Visualizations are generated by patient count, percentage and compliance distributions.

MEDICATION PERSISTENCE

• How long do new patients stay on a therapy after first prescription? Get a detailed view of treatment patterns and progression for patients within the defined market.

- · Multiple visualizations of persistence data are generated:
 - » Persistence, survivorship and episode duration distributions.
 - » Stratified visualizations: nested strata, including geographic hierarchies enable interactive analysis of persistence by multiple strata.
 - » Weekly or monthly time periods for persistence analysis.

SOURCE OF BUSINESS

· Enables interactive analysis of source-of-business data (e.g. New, Switch, Repeat transitions) for drugs across geographic locations and demographic strata. The method provides stratified visualizations, including geographic hierarchies.



Classical Statistical Applications

CLASSICAL LOGISTIC REGRESSION

 Generate Odds Ratios to assess the association between a binary outcome (presence/absence, yes/no) and multiple predictors. The method also provides additional diagnostics and supportive visualizations to identify influential observations (Deviance and Pearson Residuals) and to assess potential multi-collinearity (Variance Inflation Factor)

MH COHORT MATCH

 Uses optimized Mahalanobis algorithm to create matched cohort based on provided covariates against the final covariate as an exposure condition. Calculates metrics for closeness of match for the generated cohort against the source cohort

PROPENSITY SCORE MATCH

 Uses Propensity Score Matching algorithm to create a matched cohort based on provided covariates against the final covariate exposure condition.
 Calculates metrics for closeness of match for the generated cohort against the source cohort

MATCHED COHORT STUDY (PSM)

 Uses Propensity Score Matching algorithm to create a matched cohort based on provided covariates against the final covariate as an exposure condition. Calculates metrics for closeness of match for the generated cohort against the source cohort. After creating balanced exposed and matched cohorts, calculates incidence risk rates for each cohort. Produces various charts, excel files and a consolidated word document templating the entire study

KAPLAN MEIER

• Produce Kaplan-Meier curves for an exposure of interest. Outputs can be optionally stratified by several exposures

COX PROPORTIONAL HAZARDS

• For data with one record per patient, one or more exposures defined by binary or categorical exposure column, outcome data column with supporting Kaplan Meier plots

CLASSICAL LINEAR REGRESSION

- The classical logistic regression method allows the investigation of the association between a binary outcome variable (dependent variable) and multiple predictor variables (also known as exposure or independent variables) that can be binary, categorical, or continuous. The method is particularly of interest for those who want to express this association in terms of Odds Ratios (OR)
- As the outcome is binary (measured success/failure, presence/absence, 0/1) the logistic regression model estimates the impact of each predictor variable on the OR of the observed event of interest

Variable	Odds Ratio (OR)	OR (95% CI)	Beta	SE	Wald	Wald (95% CI)	P-value
Intercept	0	(0.000 ; 0.000)	-9.251	0.209	-44.291	(-9.661 ; -8.842)	<0.001
Gender [Female] (ref Male)	0.503	0.503 (0.456 ; 0.554)		0.05	-13.86	(-0.784 ; -0.590)	<0.001
Age_Group [36-64 years] (ref 18-35 years)	5.451	(3.707 ; 8.016)	1.696	0.197	8.62	(1.310 ; 2.081)	<0.001
Age_Group [>= 65 years] (ref 18-35 years)	13.7	(9.346 ; 20.081)	2.617	0.195	13.415	(2.235 ; 3.000)	<0.001
MODEL FAMILY:	Binomial		LO	G-LIKELIHOOD	-14178.116		
LINK FUNCTION:			LOG-LIKEI	IHOOD (NULL	-14618.718		
NO. OBSERVATIONS:	3441135	.000	-2 L	OG-LIKELIHOO	28356.233		
DF RESIDUALS:	3441126.000 8.000		PEAR	SON CHI-SQUA	3474790.439 0.03		
DF MODELS:			PSEUDO R	-SQUARE (MC F			
SCALE:	1.000)	AIC:			28374.233	
DEVIANCE:	28356.2	233	BIC:			-51765104.54	
DATE:	Tue, 09 Jur	Tue, 09 Jun 2020					
TIME:	14:16:39						

 Genomics

GENOME-WIDE ASSOCIATION STUDY (GWAS)

Method used to correlate clinical and genomic data to identify associations between genetic variants and a particular disease.





PHENOME-WIDE ASSOCIATION STUDY (PheWAS)

Method used to identify associations between genetic variants and clinical phenotypes. It is a study design in which the association between genetic variants is tested across a large number of different phenotypes.



95% confidence intervals for coefficient values variant p value < 0.01

UNDIAGNOSED PATIENTS

• Use machine learning algorithms to identify early diagnosis or potentially undiagnosed patients for an identified condition based on selected covariates

DIMENSIONAL SELECTION

• Which features matter most? Select the most important columns from the input data-frame and create a new data frame with just those columns



Index and risk strata generation

CHARLSON COMORBIDITY INDEX (CCI)

• Quantify the burden of disease by calculating the CCI based on the recorded comorbid conditions for the selected cohort

Conclusion

To achieve this level of dataset / data schema portability, analytic methods run against standardized analytical data files (typically tensor-based data with either 1 row-per-patient or 1-row-per patientevent vectors). The E360[™] Analytics Dataset Tool is a powerful utility for generically producing such files from any loaded Real-World Dataset, but the data can be sourced from any system inside or outside of E360[™].

The notion of executing an analytic **anywhere** refers to the federated analytics capabilities enabled by E360[™] Analytics Workbench with the E360[™] network execution model whereby analytic data set generation and analytic execution can be federated and distributed across a network.

To achieve **any analytic** E360[™] Analytics Workbench incorporates an open and Extensible Methods Library this allows internal development, custom development and client-based development and integration of analytical methods. It provides the infrastructure for mobilizing an internal and external developer network for analytical methods.

E360[™] Analytics Workbench provides an open environment for analytical method development and execution – not a black box.

This ability gives you access to all your RWD needs regardless of location in one platform.

CONTACT US

To find out more information about E360[™] Please contact E360Team@iqvia.com iqvia.com/E360

